Op-T is developing new therapeutics to control the chronic immune dysfunction at the core of autoimmune diseases and dysregulated inflammatory conditions
Th40 cells (CD40 expressing T cells) are elevated 3- to 5- fold in patients with autoimmune or chronic inflammatory diseases and are a key driver of inflammation.
Our peptides mimic natural binding sequences to reduce abnormal T cell activity, thereby correcting immune dysfunction at its source.
